Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference

Jacobio Pharma, a clinical-stage oncology company focusing on undruggable targets, is pleased to announce that the company will present its clinical results in the form of Proffered Paper presentation at the 2023 European Society for Medical Oncology Congress.

Scroll to Top